News & Events


Recent Firm Activities and Highlights

Odyssey Logistics & Technology
Odyssey Logistics & Technology Receives Equity Investment from The Jordan Company
08.30.17
Odyssey Logistics & Technology Corporation (Odyssey), a leading global logistics provider, announced today that an affiliate of The Jordan Company has signed a definitive agreement to become the new majority shareholder in Odyssey. Read More
Bivarus
Bivarus and Community Oncology Alliance Collaborate to Improve Oncology Patient Experience
08.29.17
Bivarus, a patient-centered analytics company, has formed a partnership with the Community Oncology Alliance (COA) to help its member practices across the country improve patient experiences. COA members can now utilize Bivarus’ survey platform to satisfy the Merit-Based Incentive Payment System (MIPS) requirements for reimbursement from the Centers for Medicare & Medicaid Services (CMS). Read More
PAREXEL International
Two PAREXEL Executives Named to 2017 PharmaVOICE 100
08.01.17
BOSTON, August 1, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer, and Evan Demestihas, M.D., RPh, Vice President, Worldwide Head of The Medical Affairs Company (TMAC), have been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2017 issue of PharmaVOICE, recognizes both leaders for their valuable contributions to the industry and dedication to improving patients’ lives, while also mentoring the next generation of industry leaders. Read More
COTA
NJ Health System Pilots IBM Watson for Oncology Decision Support
07.10.17
IBM Watson for Oncology is getting a trial run at Hackensack Meridian Health, which is supplementing the cognitive computing tool with additional clinical decision support software. Read More
COTA
Pharma turns to big data to gauge care and pricing
07.11.17
After many years building successful technology businesses, Jeremy Sohn never imagined that at 43 he would find himself on the payroll of a big pharmaceutical company. But 18 months ago he was appointed global head of digital business development and licensing at Swiss drugmaker Novartis. His appointment is evidence of how an industry, slow to respond to the disruption of digitisation, is grasping its importance as it confronts pricing pressures, ever-vaster quantities of patient data and more empowered consumers. Read More
COTA
COTA’s Pecora named Executive of the Year at NJBIZ Healthcare Heroes
06.21.17
Dr. Andrew Pecora said he was honored and humbled when he received the Health Care Executive of the Year award at the NJBIZ Healthcare Heroes awards event Tuesday. Pecora, the president of physician services and chief innovation officer at Hackensack Meridian Health, was quick to recognize his colleagues in the crowd as well as the other honorees at the event. Read More
PAREXEL International
PAREXEL International Enters Definitive Agreement to be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash
06.20.17
BOSTON and NEW YORK, June 20, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Pamplona Capital Management, LLP (Pamplona) today announced that they have entered into a definitive agreement under which Pamplona will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash in a transaction valued at approximately $5.0 billion, including PAREXEL’s net debt. Read More
COTA
Hackensack Meridian Health taps IBM Watson for help on cancer treatments
06.05.17
IBM Watson Health, Cota Healthcare and Hackensack Meridian Health are partnering to test clinical decision support in cancer treatment, a pilot that will draw on Cota's precision-medicine database and Watson Health's artificial intelligence-enabled evidence-based recommendations. Read More
Odyssey Logistics & Technology
Odyssey Logistics & Technology Recognized by Gartner in Magic Quadrant for North American 3PL
05.18.17
Danbury, Conn. (May 18, 2017) — Odyssey Logistics & Technology Corp. (Odyssey), a global leading logistics provider, today announced that it has been positioned by Gartner, Inc. on the “Magic Quadrant for Third Party Logistics Providers, North America” for 2017. This marks the first time Odyssey has been placed on the Gartner Magic Quadrant. Read More
COTA
COTA, IBM Watson teaming up for pilot program at Hackensack Meridian
05.10.17
Imagine waiting for your diagnosis. The doctor walks in and says, “Well, I just consulted with everyone on the planet Earth over the last 30 years to see how they took care of people like you, and then I looked at a database that precisely looked at people who have exactly what you have, and are exactly like you, and this is what I have learned in the past five minutes, and this is why I am going to recommend this treatment.” Read More
Odyssey Logistics & Technology
Odyssey Logistics & Technology Receives Equity Investment from The Jordan Company
08.30.17
Odyssey Logistics & Technology Corporation (Odyssey), a leading global logistics provider, announced today that an affiliate of The Jordan Company has signed a definitive agreement to become the new majority shareholder in Odyssey. Read Full Release
PAREXEL International
Two PAREXEL Executives Named to 2017 PharmaVOICE 100
08.01.17
BOSTON, August 1, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that Sy Pretorius, M.D., Senior Vice President and Chief Scientific Officer, and Evan Demestihas, M.D., RPh, Vice President, Worldwide Head of The Medical Affairs Company (TMAC), have been named to PharmaVOICE magazine’s list of the 100 most inspiring people in the life sciences industry. The honor, published in the July/August 2017 issue of PharmaVOICE, recognizes both leaders for their valuable contributions to the industry and dedication to improving patients’ lives, while also mentoring the next generation of industry leaders. Read Full Release
PAREXEL International
PAREXEL International Enters Definitive Agreement to be Acquired by Pamplona Capital Management for $88.10 Per Share in Cash
06.20.17
BOSTON and NEW YORK, June 20, 2017 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Pamplona Capital Management, LLP (Pamplona) today announced that they have entered into a definitive agreement under which Pamplona will acquire all of the outstanding shares of PAREXEL for $88.10 per share in cash in a transaction valued at approximately $5.0 billion, including PAREXEL’s net debt. Read Full Release
Odyssey Logistics & Technology
Odyssey Logistics & Technology Posts Eight Percent Growth; Continues fourteen year trend of consecutive growth
02.02.17
Danbury, Conn. (Feb. 2, 2017) — Odyssey Logistics & Technology Corporation (Odyssey) announced today that it has posted fourteen consecutive years of growth, with net revenue up eight percent in 2016. The company attributes this year’s results to sustaining its leadership position in complex key markets, implementing operational efficiencies and maximizing benefits from the acquisition of Linden Bulk Transportation. Read Full Release
COTA
BMP Invests in COTA
12.20.16
Boston Millennia Partners Invests in Cota, Inc. Boston, MA, December 2016, Boston Millennia Partners is pleased to announce its investment in Cota, Inc. as part of an $18 million growth equity round. Cota is a New York City based cancer outcomes and data tracking company that uses a patented digital classification system to assess patient results on specific treatment protocols. Cota’s customers include pharmaceutical companies, healthcare providers and insurance companies. The company has partnerships with several major pharmaceutical companies in the U.S. including Novartis and Celgene, and with data provider Foundation Medicine. The company has received strategic investments from Novartis, Celgene, Foundation Medicine and Horizon Healthcare. Read Full Release
Collegium Pharmaceutical
Jeffries Key Takeaway: Another Formulary Win Further Positions Xtampza for a Potential 1H17 Inflection
12.15.16
COLL announced another formulary “win” for Xtampza following successful contracting with ESRX, the largest US pharmacy benefits manager (PBM). Starting January 1, 2017, Xtampza will be added to ESRX’s formulary as a preferred brand with access to another 28M commercial lives. Based on steady progress with the launch and managed care wins, we continue to believe that Xtampza Rxs are positioned for an inflection in 1H17 and see the drug as a $400M+ peak product. Read Full Release
Boston Millennia Parters
Report of the Cancer Moonshot Task Force
10.17.16
While bold, the goal of the Cancer Moonshot is within our grasp. Today, society has the benefit of decades of scientific understanding and vast amounts of rich data just waiting to be transformed into solutions. We now know that cancer is hundreds of diseases, largely of our genome, and we have developed new and innovative ways of capitalizing on this knowledge. We know that our behavior and environment contribute to our likelihood of getting cancer, and we are modifying our behaviors and exposures to avoid known risks. We know that prevention and early diagnosis are key to fighting cancer, and we can build these efforts into clinical care. Read Full Release
MedAptus
MedAptus Hospitalist Customers Leverage Real-Time Data to Manage Patient Risk
10.20.16
MedAptus® today announced the availability of real-time analytics, the Hospitalist Risk Series, that leverage patient history and admission activity to identify those at greatest risk for re-admissions, and also helps providers better manage resources related to length of stay. The new Series, aimed primarily at hospitalists on the front line of acute patient care, is available through the MedAptus Professional Charge Capture (Pro) suite. This latest offering extends the Pro solution’s ability to compute data from admission/discharge feeds and diagnosis history in order to meaningfully impact key metrics around hospitalizations that hospital medicine providers are increasingly responsible for. Read Full Release
Collegium Pharmaceutical
Despite Recent Performance We Still See Room for Upside Given United Win and Xtampza ER Tailwinds for 2017
10.03.16
Following recent share performance that has shares almost doubling in the past two weeks, we continue to see room for share appreciation as the Xtampza ER launch has clear tailwinds as we exit the summer through 2017. Management has signed at least one large managed care win with UnitedHealth (UNH $140.00) and we believe additional managed care wins are likely during the fourth quarter as well as the potential for comparative data between OxyContin and Xtampza ER being added to label. Admittedly, the Xtampza ER launch was slow as management chose to launch during the summer months despite the historically slow season, which was compounded by a lack of approved marketing materials. However, the company recently received approved marketing materials and given formulary wins (both UnitedHealth and likely additional wins), we should see a ramping up of scripts over the next quarter and into 2017. Read Full Release
Collegium Pharmaceutical
Collegium Announces Publication of Data on Oral Abuse Potential of Xtampza ER
09.29.16
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) today announced the publication of “Oral Human Abuse Potential of Oxycodone DETERx® (Xtampza® ER),” in the peer-reviewed medical journal, The Journal of Clinical Pharmacology. The publication presents the results from a human abuse potential (HAP) study, which was designed to evaluate the abuse potential and pharmacokinetics of oral administration of intact Xtampza® ER (oxycodone extended-release), oral administration of chewed Xtampza ER, and oral administration of crushed immediate-release oxycodone in non-dependent, recreational drug abusers. Read Full Release
Boston Millennia Parters
Dana Callow to be Panelist at Funding Models in Biotech MBBP Life Sciences Series – Panel 3
09.22.16
Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors. So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas: Where and how to find the new players; What areas of interest are these players financing; How to optimize your chances of success; What are deal structures looking like? Read Full Release
Boston Millennia Parters
David Carney to Attend CED Tech Venture Conference
09.13.16
From early startups to growth-stage companies to highly successful businesses, the CED Tech Venture Conference reflects North Carolina’s vibrant entrepreneurial community and showcases many of the most-promising emerging companies in the region. Attendees will have the opportunity to connect with a diverse group of over 100 investors, from venture capital to corporate to angels, including funds such as Sequoia Capital, Greycroft, Grotech Ventures, and Comcast Ventures. Engage with industry leaders, radical thinkers and trail-blazing entrepreneurs, and learn about the disruptive innovations that are transforming the ways in which we live, work and play. Read Full Release
Boston Millennia Parters
Dana Callow to be on Lifescience Panel at the Richi Immersion Summer 2016 Program
07.21.16
Richi Social Entrepreneurs is a Richi Foundation initiative whose mission is to foster and catalyze the development of international Social Entrepreneurship ecosystems, taking Boston's unique case as our role model. Richi Social Entrepreneurs Immersion Summer 2016 is a one-month eye-opening experience in Boston. Social Entrepreneurs have the opportunity to explore Boston's advanced Social Innovation ecosystems, while working on their social value proposition and problem-solution fit. Social Entrepreneurs wear different hats, from startup founders in BioTech, HealthCare or Education, to professionals working in IT, CleanTech or Finance. It's not the industry that determines a project's potential social impact, it's the drive and motivation of the entrepreneur behind the idea. Read Full Release
Boston Millennia Parters
Dana Callow to Speak at Cancer Moonshot Summit
06.29.16
Boston Millennia Partners’ Dana Callow to Speak at Cancer Moonshot Summit. Simultaneous events will take place at the same time throughout the country to improve awareness of the program and gain support for funding research. Representatives from major pharmaceutical companies and service providers including Takeda, Syapse, and Foundation Medicine well as researchers from the area will speak about the Moonshot and their roles in finding a cure. The White House is sponsoring The National Cancer Moonshot summit. Vice President Joe Biden will speak on behalf of the program and subsequently there will be panel discussions by leading cancer specialists and patient advocates. As a Board Member of the National Leukemia Society Dana will address how non-profit organizations can positively impact the effort to find cures and improve patient care. Location: MGH Cancer Center, Lawrence House, 1st Floor Conference Room, 10 North Grove St., Boston MA Please contact liz@bmpvc.com for the speaker guide Read Full Release
PAREXEL International
PAREXEL Experts to Discuss Key Drug Development Insights at DIA 2016
06.20.16
BOSTON, June 20, 2016— PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that several of its experts will discuss key issues facing the industry at the 52nd Annual Drug Information Association (DIA) meeting, held from June 26-30, 2016 in Philadelphia. Read Full Release
PAREXEL International
PAREXEL Announces Master Services Agreement with Pfizer
06.10.16
BOSTON, June 10, 2016 – PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that it has signed a services agreement with Pfizer Inc. Under the terms of this agreement, PAREXEL will continue to provide global clinical research and development services to Pfizer in support of clinical development programs across its portfolio. Terms of the agreement were not disclosed. Read Full Release
PAREXEL International
PRXL to Present at Cambridge Healthtech Institute’s Twelfth Annual Biomarkers & Diagnostics World Congresss 2016
05.18.16
Presentation: Wednesday, May 18 - 9:20 am Extending Precision Medicine Beyond Oncology Arlene Hughes, Senior Director, Genomic Medicine, Clinical Research Services Visit PAREXEL at Booth 4 in the Exhibit Hall. Read Full Release
Odyssey Logistics & Technology
Odyssey Logistics & Technology (Odyssey) at World of Concrete Trade Show
02.02.15
Odyssey will have representatives from its business service, Web Integrated Network (WIN) at booth C4123. Visitors are welcome to stop by the booth to learn more about this web-based logistics management capability, and meet WIN team member, Phil Villapiano, former American football star and champion Read Full Release
Odyssey Logistics & Technology
Odyssey Logistics & Technology Receives Equity Investment from The Jordan Company
08.30.17
Odyssey Logistics & Technology Corporation (Odyssey), a leading global logistics provider, announced today that an affiliate of The Jordan Company has signed a definitive agreement to become the new majority shareholder in Odyssey. Read Full Release
Boston Millennia Parters
Dana Callow to Attend Harvard Medical School’s Precision Medicine 2017: Breakaway Business Models
06.21.17
In this year’s conference on Wednesday, June 21 (agenda below), we address the question of how to implement and disseminate these business models head on. Fortunately there are already several enterprises, some of them led by patients themselves, which provide us early answers to these questions. These are featured in our first panel entitled Early Disruptors in Precision Medicine. Read Full Release
PAREXEL International
Attend the lunch and learn with PRXL on Key Aspects of the FDA’s Drug Development and Review Programs
05.12.17
MassBio Lunch and Learn: Navigating Accelerated Approvals in Today’s Oncology Drug Development Landscape: Ensuring a Properly Tailored Approached Based on FDA Expectations and Current Trends in Drug Development Read Full Release
Boston Millennia Parters
Dana Callow to Speak on The State of The VC Market Panel
11.17.16
ACG Boston's regular networking breakfast returns to Serafina in Boston's financial district. Open to all, the Networking Breakfast is ACG Boston's signature event, where M&A professionals come to network and hear industry experts share their outlook, opinions, successes and failures. Join New England's M&A community on November 17 to hear a panel discussion on the current state of the VC market -- how the industry has evolved and where it's headed in the future. Read Full Release
Boston Millennia Parters
BMP to attend 2016 SBIR New England Regional Summit
10.06.16
The 2016 New England Regional Innovation Summit is a two-day engagement opportunity being held at MIT, for technology innovators and entrepreneurs. This effort, spearheaded by the SBA Office of Investment and Innovation (OII), is a coordinated effort amongst participating SBIR/STTR agencies to continually engage, identify, and encourage participation in the SBIR/STTR programs. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, affectionately referred as America’s Seed Fund, play an instrumental role in providing early stage, non-dilutive, research and development capital which spurs small advanced technology firms’ innovations. Annually more than $2.5 billion non-diluted in early stage research and development funding is provided through these programs. Read Full Release
Boston Millennia Parters
Dana Callow to be Panelist at Funding Models in Biotech MBBP Life Sciences Series – Panel 3
09.22.16
Today’s financing environment for emerging biotech companies presents a number of challenges. Venture capital funds are ever more cautious about taking risk, and some players have departed the field at the early stage. Government grants have also closed their spigots in recent years, as the volume of government funding has plummeted dramatically. However, new players have entered the fray in the last few years, including family offices, super angels, strategic partners and foreign investors, replacing the investment dollars previously offered by institutional investors. So where does an emerging biotech company forage for precious dollars? Come join us on September 22nd at the CIC in Cambridge to hear a panel of experts discuss these trends. At the event, you will discover, among other ideas: Where and how to find the new players; What areas of interest are these players financing; How to optimize your chances of success; What are deal structures looking like? Read Full Release
Boston Millennia Parters
2016 Wells Fargo Healthcare Conference
09.07.16
Please join us on September 7-8 for the 11th Annual Wells Fargo Securities Healthcare Conference in Boston. Read Full Release
Boston Millennia Parters
Dana Callow to be on Lifescience Panel at the Richi Immersion Summer 2016 Program
07.21.16
Richi Social Entrepreneurs is a Richi Foundation initiative whose mission is to foster and catalyze the development of international Social Entrepreneurship ecosystems, taking Boston's unique case as our role model. Richi Social Entrepreneurs Immersion Summer 2016 is a one-month eye-opening experience in Boston. Social Entrepreneurs have the opportunity to explore Boston's advanced Social Innovation ecosystems, while working on their social value proposition and problem-solution fit. Social Entrepreneurs wear different hats, from startup founders in BioTech, HealthCare or Education, to professionals working in IT, CleanTech or Finance. It's not the industry that determines a project's potential social impact, it's the drive and motivation of the entrepreneur behind the idea. Read Full Release
Boston Millennia Parters
Dana Callow to Speak at Cancer Moonshot Summit
06.29.16
Boston Millennia Partners’ Dana Callow to Speak at Cancer Moonshot Summit. Simultaneous events will take place at the same time throughout the country to improve awareness of the program and gain support for funding research. Representatives from major pharmaceutical companies and service providers including Takeda, Syapse, and Foundation Medicine well as researchers from the area will speak about the Moonshot and their roles in finding a cure. The White House is sponsoring The National Cancer Moonshot summit. Vice President Joe Biden will speak on behalf of the program and subsequently there will be panel discussions by leading cancer specialists and patient advocates. As a Board Member of the National Leukemia Society Dana will address how non-profit organizations can positively impact the effort to find cures and improve patient care. Location: MGH Cancer Center, Lawrence House, 1st Floor Conference Room, 10 North Grove St., Boston MA Please contact liz@bmpvc.com for the speaker guide Read Full Release
PAREXEL International
DIA Annual Meeting
06.26.16
DIA 2016 52nd Annual Meeting Read Full Release